Other News To Note
APP Pharmaceuticals Inc., of Schaumburg, ILL., and The Medicines Co. (MDCO), of Parsippany, N.J., settled litigation related to APP's abbreviated new drug application for a generic version of the anti-clotting drug Angiomax (bivalirudin for injection). MDCO licensed APP to begin selling APP's generic version of Angiomax in the U.S. on May 1, 2019, or earlier, in certain circumstances.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST